Advertisement

Pathology Oncology Research

, Volume 9, Issue 3, pp 174–179 | Cite as

Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients

“A pre-gleevec study”
  • László Kereskai
  • János A. Vass
  • Maria Kneif
  • László Pajor
Article

Abstract

The interferon treatment of chronic myeloid leukaemia has been monitored by investigating the tumour burden as revealed by fluorescence in situ hybridization and the expression of BCR-ABL chimera determined by quantitative reverse transcription polymerase chain reaction. These parameters were obtained from the peripheral blood of 51 untreated and 104 follow-up patient samples. Poor corrrelation (r =.31) was found between BCR-ABL expression and tumor load in all samples as well as in untreated patients, and this correlation was even less in all follow-up cases (r =.28). Regarding chimera expression five order of magnitude difference existed in the untreated patients and this value dropped to two in those with complete cytogenetic response. Only the major and the complete cytogenetic response groups differed significantly (p.001) in the BCR-ABL expression from that of patients at diagnosis. Among the different cytogenetic response groups the only significant difference (p <.01) in the BCR-ABL expression was obtained between the major and the minor responders. In the individual patients not only correlated changes of residual tumour mass and chimera expression, but mainly independent changes of these two parameters were observed. This indicates that the BCR-ABL expression and the tumor burden are largely independent variables.

Keywords

chronic myeloid leukaemia molecular monitoring quantitative polymerase chain reaction fluorescence in situ hybridisation 

List of abbreviations

Bcr

breakpoint cluster region

bcr-abl

chimera of bcr and abl gene

BMT

bone marrow transplantation

CCA

conventional cytogenetic analysis

cDNA

copy DNA

CML

chronic myeloid leukemia

FISH

fluorescence in situ hybridization

IFN

interferon

IPC

interphase cytogenetics

M-bcr

major bcr

MMLV-RT

Maloney Murine Leukemia Virus Reverse Transcriptase

PCR

polymerase chain reaction

Ph

Philadelphia chromosome

Q-PCR

quantitative reverse transcription polymerase chain reaction

RT

reverse transcription

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bedi A, Zehnbauer BA, Collector MI, et al: BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 81: 2898–2902, 1993PubMedGoogle Scholar
  2. 2.
    Bentz M, Cabot G, Moos M, et al: Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukaemia by in situ hybridization. Blood 83: 1922–1928, 1994PubMedGoogle Scholar
  3. 3.
    Brizard F, Chomel JC, Veinstein A, et al: Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon therapy? Leukemia 12: 1076–1080, 1998PubMedCrossRefGoogle Scholar
  4. 4.
    Cuneo A, Bigoni R, Emmanuel B, et al: Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia 12: 1718–1723, 1998PubMedCrossRefGoogle Scholar
  5. 5.
    Dewald GW, Schad CR, Christensen ER, et al: The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL. Cancer Genet Cytogen 71: 7–14, 1993CrossRefGoogle Scholar
  6. 6.
    Faderl S, Talpaz M, Kantarjian HM, et al: Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 93: 2755–2759, 1999PubMedGoogle Scholar
  7. 7.
    Furukawa Y, Iwase S: Antileukemic effect of interferon-a is mediated through down-modulation of E2F activity. Leukemia 11: 446–448, 1997PubMedGoogle Scholar
  8. 8.
    Gaiger A, Henn T, Hörth E, et al: Increase of BCR-ABL chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 86: 2371–2378, 1995PubMedGoogle Scholar
  9. 9.
    Garcia-Isidoro M, Tabernero MD, Garcia JL, et al: Detection of the Mbcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: Comparison with conventional cytogenetics and implication for minimal residual disease detection. Hum Pathol 28: 154–159, 1997PubMedCrossRefGoogle Scholar
  10. 10.
    Hermans A, Gow J, Selleri L, et al: Bcr-abl oncogene activation in Philadelphia chromosome-positiv acute lymphoblastic leukemia. Leukemia 2: 628–633, 1988PubMedGoogle Scholar
  11. 11.
    Hochhaus A, Lin F, Reiter A, et al: Quantification of residual disease in chronic myelogeneous leukemia patients on Interferon-α therapy by competitive polymerase chain reaction. Blood 87: 1549–1555, 1996PubMedGoogle Scholar
  12. 12.
    Hochhaus A, Reiter A, Skladny H, et al: Molecular heterogeneity in complete cytogenetic responders after interferon—therapy of chronic myelogenous leukemia: levels of minimal residual disease predict risk of relapse. Blood 88 (suppl. 1): 664a. (abstr. No 2644), 1996Google Scholar
  13. 13.
    Hochhaus A, Lin F Reiter A, et al: Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-. Brit J Haematol 91: 126–131, 1995CrossRefGoogle Scholar
  14. 14.
    Hochhaus A, Weisser A, La Rosée P, et al: Detection and quantification of residual disease in chronic myelogeneous leukemia. Leukemia 14: 998–1005, 2000PubMedCrossRefGoogle Scholar
  15. 15.
    Issaad C, Ahmed M, Novault S, et al: Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7. Leukemia 14: 662–670, 2000PubMedCrossRefGoogle Scholar
  16. 16.
    Jakab Z, Balogh E, Kiss C, et al: Biclonal chromosomal aberrations in a child with myelodysplastic syndrome. Cancer Genet Cytogen 108: 13–18, 1999CrossRefGoogle Scholar
  17. 17.
    Kantarjian HM, Deisseroth A, Kurzrock R, et al: Chronic myelogenous leukemia: A concise update. Blood 82: 691–703, 1993PubMedGoogle Scholar
  18. 18.
    Kantarjian HM, O’Brien S, Anderlini P, et al: Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 87: 3069–3081, 1996PubMedGoogle Scholar
  19. 19.
    Kantarjian HM, Smith TL, O’Brian S, et al: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to Interferontherapy. Ann Intern Med 122: 254–261, 1995PubMedGoogle Scholar
  20. 20.
    Keating A, Xing-Hua Wang XH, Laraya P: Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 83: 1744–1749Google Scholar
  21. 21.
    Lion T, Gaiger A, Henn T, et al: Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia 9: 1353–1360, 1995PubMedGoogle Scholar
  22. 22.
    Moore S, Haylock DN, Levesque JP, et al: Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells. Blood 92: 2461–2470, 1998PubMedGoogle Scholar
  23. 23.
    Mühlmann J, Thaler J, Hilbe W, et al: Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during Interferon treatment: A new strategy for remission assessment. Gene Chromosome Canc 21: 90–100, 1998CrossRefGoogle Scholar
  24. 24.
    Pajor L, Szuhai K, Méhes G, et al: Combined metaphase, interphase cytogenetic, and flow cytometric analysis of DNA content of pediatric acute lymphoblastic leukaemia. Cytometry 34: 87–94, 1998PubMedCrossRefGoogle Scholar
  25. 25.
    Pajor L, Vass JA, Kereskai L, et al: Silent Philadelphia chromosome: A distinct developmental stage in a Philadelphia chromosome-positive chronic myeloproliferation? Cancer Genet Cytogen 118: 14–19, 2000CrossRefGoogle Scholar
  26. 26.
    Reiter A, Marley SB, Hochhaus A, et al: BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha. Brit J Haematol 102: 1271–1278, 1998CrossRefGoogle Scholar
  27. 27.
    Shtivelman E, Gale RP, Dreazen O, et al: bcr-abl RNA in patients with chronic myelogenous leukaemia. Blood 69: 971–973, 1987PubMedGoogle Scholar
  28. 28.
    Talpaz M, Kantarjian HM, Kurznock R, et al: Interferon-alfa produces sustained cytogenetic responses in chronic myelogenous leukaemia Ph-chromosome positive patients. Ann Intern Med 114: 532–538, 1991PubMedGoogle Scholar
  29. 29.
    Tchirkov A, Giollant M, Tavernier F, et al: Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferontherapy. Brit J Haematol 101: 552–557, 1998CrossRefGoogle Scholar
  30. 30.
    The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon Alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 330: 820–825, 1994CrossRefGoogle Scholar
  31. 31.
    Verfaillie CM, Bhatia R, Miller W, et al: BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 87: 4770–4779, 1996PubMedGoogle Scholar
  32. 32.
    Yanagi M, Shinjo K, Takeshita A, et al: Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells. Leukemia 13: 542–552, 1999PubMedCrossRefGoogle Scholar
  33. 33.
    Zhang JG, Lin F, Chase A, et al: Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood 87: 2588–2593, 1996PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2003

Authors and Affiliations

  • László Kereskai
    • 1
  • János A. Vass
    • 1
  • Maria Kneif
    • 1
  • László Pajor
    • 1
  1. 1.Faculty of Medicine, Department of PathologyUniversity of PécsPécsHungary

Personalised recommendations